STING1 and triple-A syndrome: Following the validation of the stability of this organoid culture system, we commenced pharmacological treatment of AAA PDO derived from samples of Patient 10 on the third day of cultivation with 1 μM RU.521 (RU), 1 μM STING-IN-2 (ST), accompanied by a solvent control and another control of 1 μM metformin (Met), which has the potential for the treatment of AAA 22, 39, 40.